P
Paul Ellis
Researcher at King's College London
Publications - 95
Citations - 8567
Paul Ellis is an academic researcher from King's College London. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 37, co-authored 93 publications receiving 7786 citations. Previous affiliations of Paul Ellis include King's College & St Thomas' Hospital.
Papers
More filters
Journal ArticleDOI
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse,Sherene Loi,Laura J. van't Veer,Giuseppe Viale,Mauro Delorenzi,Annuska M. Glas,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Bogaerts,Patrick Therasse,Arno Floore,Mohamed Amakrane,Fanny Piette,Emiel J. Th. Rutgers,Christos Sotiriou,Fatima Cardoso,Martine Piccart +19 more
TL;DR: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.
Journal ArticleDOI
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
Sherene Loi,Benjamin Haibe-Kains,Christine Desmedt,Françoise Lallemand,Andrew Tutt,Cheryl Gillet,Paul Ellis,Adrian L. Harris,Jonas Bergh,John A. Foekens,Jan Klijn,Denis Larsimont,Marc Buyse,Gianluca Bontempi,Mauro Delorenzi,Martine Piccart,Christos Sotiriou +16 more
TL;DR: The use of genomic grade can identify two clinically distinct ER-positive molecular subtypes in a simple and highly reproducible manner across multiple data sets and emphasizes the important role of proliferation-related genes in predicting prognosis in ER- positive BC.
Journal ArticleDOI
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial
Andrew Tutt,Andrew Tutt,Holly Tovey,Maggie C.U. Cheang,Sarah Kernaghan,Lucy Kilburn,Patrycja Gazinska,Julie Owen,Jacinta Abraham,Sophie Barrett,Peter Barrett-Lee,Robert S. Brown,Robert S. Brown,Stephen Chan,Mitchell Dowsett,Mitchell Dowsett,James M. Flanagan,Lisa Fox,Anita Grigoriadis,Alexander Gutin,Catherine Harper-Wynne,Matthew Hatton,Katherine A. Hoadley,Jyoti Parikh,Peter J. Parker,Peter J. Parker,Charles M. Perou,Rebecca Roylance,Vandna Shah,Adam Shaw,Ian E. Smith,Kirsten Timms,Andrew M Wardley,Gregory C. Wilson,Cheryl Gillett,Jerry S. Lanchbury,Alan Ashworth,Nazneen Rahman,Nazneen Rahman,Mark Harries,Paul Ellis,Sarah E Pinder,Judith M Bliss +42 more
TL;DR: The phase 3 TNT Trial in subjects with triple-negative breast cancer supports the superiority of carboplatin over docetaxel in BRCA1/2-mutated tumors and a greater response to taxanes in the nonbasal subtype, and concludes that patients with advanced TNBC benefit from characterization of BRC a/2 mutations, but not BRC1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.
Journal ArticleDOI
Adjuvant trastuzumab for HER2-positive breast cancer.
TL;DR: It is unusual to see any such effect on survival so early in an adjuvant breast cancer trial, but trastuzumab is rapidly becoming the standard of care after surgery for high-risk HER2-positive breast cancer.
Journal ArticleDOI
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Charles Butts,Nevin Murray,Andrew Maksymiuk,Glenwood D. Goss,Ernie Marshall,Denis Soulières,Yvon Cormier,Peter M. Ellis,Allan Price,Ravinder Sawhney,Mary M. Davis,Janine Mansi,Colum Smith,Dimitrios Vergidis,Paul Ellis,Mary MacNeil,Martin Palmer +16 more
TL;DR: In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed, and maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity.